Global Immunology Drugs Market to 2023 - Shifting Landscape as Uptake of Interleukin Receptor Inhibitors Offsets Losses for Top Blockbuster Drugs
Global Immunology Drugs Market to 2023 - Shifting Landscape as Uptake of Interleukin Receptor Inhibitors Offsets Losses for Top Blockbuster Drugs

The Business Research Store is run by Sector Publishing Intelligence Ltd. SPi has been selling professional market research reports and company analyses for over 7 years. Our experienced staff team are on hand to help with any research enquiries you may have, and help you find the right report for your needs. We sell reports to businesses of all sizes across the world who need current market data to plan and develop their business strategies.

We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use How To Buy information on the last page of this document.

We look forward to being of service to you.

If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf.

Phone: +44 (0)1305 753769 or Email: office@sectorpublishing.com
Global Immunology Drugs Market to 2023 - Shifting Landscape as Uptake of Interleukin Receptor Inhibitors Offsets Losses for Top Blockbuster Drugs

Summary

Immune-mediated inflammatory diseases are a common set of chronic disorders that affect 5-7% of people in Western populations.

Although they are often disparate in terms of their symptoms and key patient demographics, they are pathophysiologically linked, being characterized by dysregulation of immune pathways and an inappropriate immune response.

This report covers all immunological disorders, but there is a particular focus on four key diseases, rheumatoid arthritis, psoriasis, inflammatory bowel disease and graft versus host disease/transplant rejection, as these conditions have the largest pipelines within the therapy area.

The market size for immunology therapeutics was valued at $65.1 billion in 2016 and it is expected to grow at a compound annual growth rate (CAGR) of 8.2% to $113 billion in 2023.

Scope

- The immunology market landscape is expected to change. Biosimilar competition is expected to affect the revenue of the big blockbuster drugs, and novel targets are expected to enter the market and drive market growth.

- Overall, there are 2,070 immunology products in the pipeline.

- Which molecular targets are most prominent within the pipeline?

- How do the key indications differ in terms of molecule type?

- How does the composition of the pipeline compare with that of the existing market?

- What mechanisms of action are most common for pipeline drugs?

- The market size for immunology therapeutics is expected to grow, from $65.1 billion in 2016 to $113 billion in 2023, at a CAGR of 8.2%.

- Which products will contribute to market growth most, and which will achieve blockbuster status?

- Will the current market leaders retain their dominance over the forecast period, and how is their revenue share of the dermatology market set to change?

- What CAGR will these companies register in the forecast period?
- How many strategic consolidations have been completed in the past decade?
- Which types of assets attract the largest deal values?

Reasons to buy

- Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis and the treatment options available at each stage of diagnosis for the four key indications.
- Visualize the composition of the immunology market overall and across each indication, in terms of dominant molecule types and targets, highlighting the key commercial assets and players.
- Stratify the market in terms of the split between generic and premium products and assess the role of these product types in the treatment of the various immunological conditions.
- Identify trends and developments, in terms of molecule type and molecular target, within the overall immunology pipeline, as well as for each of the four key indications.
- Understand the growth in patient epidemiology and market revenues for the dermatology market globally, and across the key players and product types.
- Consider market opportunities and potential risks by examining trends in clinical trial duration and size, as well as clinical trial failure rates, by stage of development, key indication, molecule type and molecular target.
- Recognize how the evolving treatment landscape will drive market growth to 2023 and understand the contributions that different products, molecular targets and companies will make to this growth.
- Identify commercial opportunities in the immunology deals landscape by analyzing trends in licensing and co-development deals.

Additional Details

Publisher: GBI Research
Reference:
Number of Pages: 181
Report Format: PDF
Publisher Information:
Table Of Contents for Global Immunology Drugs Market to 2023 - Shifting Landscape as Uptake of Interleukin Receptor Inhibitors Offsets Losses for Top Blockbuster Drugs

- 1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Therapy Area Overview
2.1.1 Rheumatoid Arthritis
2.1.2 Psoriasis
2.1.3 Inflammatory Bowel Disease
2.1.4 Graft Versus Host Disease and Transplant Rejection
2.2 Symptoms
2.3 Diagnosis
2.3.1 Rheumatoid Arthritis
2.3.2 Psoriasis
2.3.3 Inflammatory Bowel Disease
2.3.4 Graft Versus Host Disease and Transplant Rejection
2.4 Etiology and Pathophysiology
2.4.1 Rheumatoid Arthritis
2.4.2 Psoriasis
2.4.3 Inflammatory Bowel Disease
2.4.4 Graft Versus Host Disease and Transplant Rejection
2.5 Epidemiology
2.5.1 Rheumatoid Arthritis
2.5.2 Psoriasis
2.5.3 Inflammatory Bowel Disease
2.5.4 Graft Versus Host Disease and Transplant Rejection
2.6 Co-morbidities and Complications
2.7 Treatment
3 Key Marketed Products
3.1 Overview
3.2 Humira (adalimumab) - AbbVie
3.3 Enbrel (etanercept) - Amgen
3.4 Remicade (infliximab) - Johnson & Johnson
3.5 Rituxan (rituximab) - Roche
3.6 Stelara (ustekinumab) - Johnson & Johnson
3.7 Simponi (golimumab) - Johnson & Johnson
3.8 Orencia (abatacept) - Bristol-Myers Squibb
3.9 Tysabri (natalizumab) - Biogen
3.10 Actemra (tocilizumab) - Roche
3.11 Prograf (tacrolimus) - Astellas
3.12 Cimzia (certolizumab) - UCB
3.13 Entyvio (vedolizumab) - Takeda
3.14 Cosentyx (secukinumab) - Novartis
3.15 Otezla (apremilast) - Celgene
3.16 Xeljanz (tofacitinib) - Pfizer
3.17 Taltz (ixekizumab) - Eli Lilly
4 Pipeline Landscape Assessment
4.1 Overview
4.2 Pipeline Development Landscape
4.3 Molecular Targets in the Pipeline
4.4 Clinical Trials Landscape
4.4.1 Clinical Trial Failure Rates
4.4.2 Clinical Trial Duration
4.5 Assessment of Key Late-Stage Pipeline Products
4.5.1 Filgotinib - Galapagos and Gilead Sciences
4.5.2 AR-101 - Aimmune Therapeutics
4.5.3 Upadacitinib tartrate - AbbVie
4.5.4 Lanadelumab - Shire
4.5.5 Ozanimod hydrochloride - Celgene
4.6 Conclusion
5 Multi-scenario Market Forecast to 2023
5.1 Overall Market Size
5.2 Generic Penetration
5.3 Revenue Forecast by Molecular Target
5.3.1 Cytokines and Cytokine Receptors
5.3.2 Intracellular Signal Transducers
5.3.3 Cell Surface Antigens
5.3.4 Intercellular Interaction and Adhesion Molecules
5.3.5 Cell Surface Antigens
5.3.6 Viruses
6 Company Analysis and Positioning
6.1 Revenue and Market Share Analysis by Company
6.1.1 AbbVie
6.1.2 Johnson & Johnson
6.1.3 Novartis
6.1.4 Pfizer
6.1.5 Roche
6.1.6 Amgen
6.1.7 Celgene
6.1.8 Eli Lilly
6.2 Overall Market Size
6.3 Company Landscape
6.4 Marketed and Pipeline Portfolio Analysis
7 Strategic Consolidations
7.1 Licensing Deals
7.1.1 Deals by Region, Year and Value
7.1.2 Deals by Indication
7.1.3 Deals by Stage of Development
7.1.4 Deals by Molecule Type
7.1.5 Table for Licensing Deals with Disclosed Values
7.2 Co-development Deals
7.2.1 Deals by Region, Year and Value
7.2.2 Deals by Indication
7.2.3 Deals by Stage of Development
7.2.4 Deals by Molecule Type
7.2.5 Table for Co-development Deals with Disclosed Values
7.3 Figures of All Clinical Stage Pipeline Products
8 Appendix
8.1 References
8.2 Figures of All Clinical Stage Pipeline Products
8.3 Abbreviations
8.4 Disease List
9 Contact Us
10 Disclaimer
List Of Tables in Global Immunology Drugs Market to 2023 - Shifting Landscape as Uptake of Interleukin Receptor Inhibitors Offsets Losses for Top Blockbuster Drugs

1.1 List of Tables

Table 1: Immunology Drugs Market, Global, Symptoms of RA, Psoriasis and IBD, 2018 17
Table 2: Immunology Drugs Market, Global, Organ-Specific Symptoms of Transplant Rejection, 2018 18
Table 3: Immunology Drugs Market, Global, Organ-Specific Symptoms of Acute GVHD, 2018 18
Table 4: Immunology Drugs Market, Global, Organ-Specific Symptoms of Chronic GVHD, 2018 19
Table 5: Immunology Drugs Market, Etiology of RA, Psoriasis, IBD and GVHD, 2018 21
Table 6: Immunology Drugs Market, 7MM, Epidemiology of Key Immunology Indications, 2018 27
Table 7: Immunology Drugs Market, Global, Approved Indications for Humira, 2018 41
Table 8: Immunology Drugs Market, Global, Approved Indications for Enbrel, 2018 44
Table 9: Immunology Drugs Market, Global, Approved Indications for Remicade, 2018 46
Table 10: Immunology Drugs Market, Global, Approved Indications for Rituxan, 2018 49
Table 11: Immunology Drugs Market, Global, Approved Indications for Stelara, 2018 51
Table 12: Immunology Drugs Market, Global, Approved Indications for Simponi, 2018 53
Table 13: Immunology Drugs Market, Global, Approved Indications for Ocrecia, 2018 55
Table 14: Immunology Drugs Market, Global, Approved Indications for Tysabri, 2018 57
Table 15: Immunology Drugs Market, Global, Approved Indications for Actemra, 2018 59
Table 16: Immunology Drugs Market, Global, Approved Indications for Prograf, 2018 61
Table 17: Immunology Drugs Market, Global, Approved Indications for Cimzia, 2018 62
Table 18: Immunology Drugs Market, Global, Approved Indications for Entyvio, 2018 64
Table 19: Immunology Drugs Market, Global, Approved Indications for Cosentyx, 2018 66
Table 20: Immunology Drugs Market, Global, Approved Indications for Otezla, 2018 67
Table 21: Immunology Drugs Market, Global, Approved Indications for Xeljanz, 2018 69
Table 22: Immunology Drugs Market, Global, Approved Indications for Taltz, 2018 70
Table 23: Immunology Drugs Market, Global, Annual Revenue Forecast for Key Products ($m), 2016-2023 103
Table 24: Immunology Drugs Market, Global, Usage of Generics Across Key Indications, 2018 105
Table 25: Immunology Drugs Market, Global, Forecast Revenue by Company (%), 2016-2023 113
List Of Figures, Charts and Diagrams in Global Immunology Drugs Market to 2023 - Shifting Landscape as Uptake of Interleukin Receptor Inhibitors Offsets Losses for Top Blockbuster Drugs

1.2 List of Figures

Figure 1: Immunology Drugs Market, 7MM, Epidemiology Patterns for Rheumatoid Arthritis, 2016-2023 28
Figure 2: Immunology Drugs Market, 7MM, Epidemiology Patterns for Psoriasis, 2016-2023 29
Figure 3: Immunology Drugs Market, 7MM, Epidemiology Patterns for Crohn’s Disease, 2016-2023 30
Figure 4: Immunology Drugs Market, Epidemiology Patterns for Ulcerative colitis, 2016-2023 30
Figure 5: Immunology Drugs Market, Epidemiology Patterns for Graft Versus Host Disease, 2016-2023 31
Figure 6: Immunology Drugs Market, Global, Key Marketed Products and Approved Indications, 2018 40
Figure 7: Immunology Drugs Market, Global, Annual Revenues for Humira ($bn), 2006-2023 43
Figure 8: Immunology Drugs Market, Global, Annual Revenue for Enbrel ($bn), 2006-2023 45
Figure 9: Immunology Drugs Market, Global, Annual Revenue for Remicade ($bn), 2006-2023 48
Figure 10: Immunology Drugs Market, Global, Annual Revenue for Rituxan ($bn), 2006-2023 50
Figure 11: Immunology Therapeutics Market, Global, Annual Revenue for Stelara ($bn), 2010-2023 52
Figure 12: Immunology Drugs Market, Global, Annual Revenue for Simponi ($bn), 2010-2023 54
Figure 13: Immunology Drugs Market, Global, Annual Revenue for Orencia ($bn), 2006-2023 56
Figure 14: Immunology Drugs Market, Global, Annual Revenue for Tysabri ($bn), 2006-2023 58
Figure 15: Immunology Drugs Market, Global, Annual Revenues for Actemra ($bn), 2006-2023 60
Figure 16: Immunology Drugs Market, Global, Annual Revenue for Prograf ($bn), 2006-2023 62
Figure 17: Immunology Drugs Market, Global, Annual Revenue for Cimzia ($bn), 2008-2023 63
Figure 18: Immunology Drugs Market, Global, Annual Revenue for Entyvio ($bn), 2014-2023 65
Figure 19: Immunology Drugs Market, Global, Annual Revenue for Cosentyx ($bn), 2015-2023 66
Figure 20: Immunology Drugs Market, Global, Annual Revenue for Otezla($bn), 2014-2023 68
Figure 21: Immunology Drugs Market, Global, Annual Revenues for Xeljanz ($bn), 2012-2023 70
Figure 22: Immunology Drugs Market, Global, Annual Revenue for Taltz ($bn), 2016-2023 71
Figure 23: Immunology Drugs Market, Global, Overall Pharmaceutical Industry Pipeline by Therapy Area, 2018 72
Figure 24: Immunology Drugs Market, Global, Pipeline by Stage of Development and Molecule Type, 2018 73
Figure 25: Immunology Drugs Market, Global, Pipeline by Program Type, 2018 74
Figure 26: Immunology Drugs Market, Global, Pipeline for Key Immunology Indications by Stage of Development, 2018 75

Figure 27: Immunology Drugs Market, Global, Pipeline for Key Immunology Indications by Molecule Type, 2018 76

Figure 28: Immunology Drugs Market, Pipeline by Molecular Target, 2018 78

Figure 29: Immunology Drugs Market, Global, Pipeline for Key Immunology Indications by Molecular Target, 2018 79

Figure 30: Immunology Drugs Market, Global, Clinical Trial Failure Rates and Overall Clinical Trial Attrition Rate by Stage of Development (%), 2006-2018 80

Figure 31: Immunology Drugs Market, Global, Clinical Trial Failure Rates by Key Indication and Stage of Development (%), 2006-2017 81

Figure 32: Immunology Drugs Market, Global, Clinical Trial Failure Rates by Molecule Type and Stage of Development (%), 2006-2017 81

Figure 33: Immunology Drugs Market, Global, Clinical Trial Failure Rates by Molecular Target and Stage of Development (%), 2006-2017 82

Figure 34: Immunology Drugs Market, Global, Clinical Trial Duration by Stage of Development (months), 2006-2017 83

Figure 35: Immunology Drugs Market, Global, Clinical Trial Duration by Key Indication and Stage of Development (months), 2006-2017 84

Figure 36: Immunology Drugs Market, Global, Clinical Trial Duration by Molecule Type and Stage of Development (months), 2006-2017 85

Figure 37: Immunology Drugs Market, Global, Clinical Trial Duration by Molecular Target and Stage of Development (months), 2006-2017 86

Figure 38: Immunology Drugs Market, Global, Clinical Trial Size by Stage of Development (participants), 2006-2017 86

Figure 39: Immunology Drugs Market, Global, Clinical Trial Size by Key Indication and Stage of Development (participants), 2006-2017 87

Figure 40: Immunology Drugs Market, Global, Clinical Trial Size by Stage of Development and Molecule Type (participants), 2006-2017 88

Figure 41: Immunology Drugs Market, Global, Clinical Trial Size by Molecular Target and Stage of Development (participants), 2006-2017 89

Figure 42: Immunology Drugs Market, Global, Clinical Program Size by Stage of Development (participants), 2006-2017 90

Figure 43: Immunology Drugs Market, Global, Clinical Program Size by Key Indication and Stage of Development (participants), 2006-2017 91

Figure 44: Immunology Drugs Market, Global, Clinical Program Size by Molecule Type and Stage of Development (participants), 2006-2017 92

Figure 45: Immunology Drugs Market, Global, Clinical Program Size by Molecular Target and Stage of Development (participants), 2006-2017 93

Figure 46: Immunology Drugs Market, Global, Annual Revenue Forecast for Filgotinib ($m), 2019-2023 94
How to Buy...

Global Immunology Drugs Market to 2023 - Shifting Landscape as Uptake of Interleukin Receptor Inhibitors Offsets Losses for Top Blockbuster Drugs

Option 1 - Online
Go to our website and pay online with any major debit or credit card:
https://www.businessresearchstore.com/product/936052

Option 2 - Request a Proforma Invoice
Fill in the details below, and either Scan this page and email it to us at office@sectorpublishing.com or Fax it to us at +44 (0)1305 791844. We will send you a Proforma Invoice and deliver your report on settlement.

Your Name: ____________________________
Job Title: ______________________________
Your Email: ____________________________
Your Contact Phone: ____________________
Company Name: ________________________
Address: _______________________________
Post/Zip Code: _________________________
Country: _______________________________
P.O. Number: __________________________
Any Other Instructions: ___________________

Pricing Options: (please tick one)
- $4995 | Single User Price
- $9990 | Site License Price
- $14985 | Enterprise License Price

Payment Options: (please tick one)
- Online Credit Card (we will email you the invoice with a payment link)
- Direct Wire Transfer (we will email you the invoice with our bank details)

Authorising Signature: ____________________

Option 3 - Phone Us on +44 (0)1305 753769
We will be delighted to give you our personal attention.